Trial Profile
Toward a Risk-adapted Strategy to Cure Myeloma : An Intensive Program With Lenalidomide, Ixazomib, and Dexamethasone Plus Daratumumab as Extended Induction and Consolidation Followed by Lenalidomide Maintenance in Newly Diagnosed Standard Risk Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant : a Phase II Study of the Intergroupe Francophone du Myélome (IFM)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Feb 2022
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary) ; Dexamethasone (Primary) ; Ixazomib (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 14 Dec 2021 Results (n=45)presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 01 Feb 2019 Status changed from not yet recruiting to recruiting.
- 21 Sep 2018 New trial record